Imagine a child facing a second or third chance at leukemia, where standard drugs have already failed. This study looked at 340 children across 17 European countries who had relapsed or refractory acute lymphoblastic leukemia. Instead of guessing, doctors used Drug Response Profiling, a method that tests how cells react to different medicines like venetoclax and tyrosine kinase inhibitors. The goal was simple: find the one drug that actually works for that specific child.
The results were encouraging. Among those tested, 68% showed a clear positive response to the chosen treatment. For 42 patients, this successful match allowed doctors to bridge them to cellular therapies, a powerful next step. Of those 42, 28 are still alive, showing a 67% survival rate for this specific group. The data also suggests better survival chances for those who responded best to venetoclax.
However, we must be careful not to read too much into this yet. The study did not report safety issues or side effects, which is a gap we need to fill before widespread use. Also, because this was a registry of specific high-risk patients, we cannot assume these results apply to every child with leukemia. This approach enables individualized therapy selection, but it is a tool for precision trials, not a guaranteed solution for everyone.